142 related articles for article (PubMed ID: 2347058)
1. A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.
Langenbuch T; Mross K; Jonat W; Hossfeld DK
Cancer Chemother Pharmacol; 1990; 26 Suppl():S93-6. PubMed ID: 2347058
[TBL] [Abstract][Full Text] [Related]
2. Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil.
Ghavamzadeh A
Cancer Chemother Pharmacol; 1990; 26 Suppl():S66-8. PubMed ID: 2347052
[TBL] [Abstract][Full Text] [Related]
3. Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer.
Gurney H; Harnett P; Stuart-Harris R; Kefford R
Eur J Cancer; 1995 Oct; 31A(11):1773-7. PubMed ID: 8541098
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
Miglietta L; Marenghi C; Nizzo R; Foglia G; Ragni N; Boccardo F
Oncology; 2001; 60(2):116-22. PubMed ID: 11244325
[TBL] [Abstract][Full Text] [Related]
5. Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer.
Haas R; Schmid H; Hahn U; Hohaus S; Goldschmidt H; Murea S; Kaufmann M; Wannenmacher M; Wallwiener D; Bastert G; Hunstein W
Eur J Cancer; 1997 Mar; 33(3):372-8. PubMed ID: 9155519
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide combination chemotherapy in advanced breast cancer.
Schmid H; Kaufmann M; Grischke EM; Bastert G
Cancer Chemother Pharmacol; 1990; 26 Suppl():S71-3. PubMed ID: 2347055
[TBL] [Abstract][Full Text] [Related]
7. Epidoxorubicin plus ifosfamide in advanced and/or metastatic soft-tissue sarcomas.
Toma S; Coialbu T; Biassoni L; Folco U; Gatti C; Canavese G; Giacchero A; Rosso R
Cancer Chemother Pharmacol; 1990; 26(6):453-6. PubMed ID: 2121378
[TBL] [Abstract][Full Text] [Related]
8. Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study.
Chevallier B; Leyvraz S; Olivier JP; Fargeot P; Facchini T; Vo Van ML
Cancer Invest; 1993; 11(2):135-9. PubMed ID: 8462014
[TBL] [Abstract][Full Text] [Related]
9. Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours.
Hoffmann W; Weidmann B; Migeod F; Könner J; Seeber S
Cancer Chemother Pharmacol; 1990; 26 Suppl():S69-70. PubMed ID: 2347053
[TBL] [Abstract][Full Text] [Related]
10. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide, mesna and epirubicin as second-line chemotherapy in advanced breast cancer.
Kiraz S; Baltali E; Güler N; Barista I; Benekli M; Celik I; Güllü IH; Kars A; Tekuzman G; Firat D
J Chemother; 1996 Aug; 8(4):310-4. PubMed ID: 8873839
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of ifosfamide plus high-dose epirubicin in advanced non-small-cell lung cancer.
Gridelli C; Rossi A; Incoronato P; Bruni GS; Scognamiglio F; Ruffolo P; Rinaldi L; Bianco AR
Cancer Chemother Pharmacol; 1996; 37(6):613-5. PubMed ID: 8612318
[TBL] [Abstract][Full Text] [Related]
13. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide, methotrexate, and 5-fluorouracil: effective combination in resistant breast cancer.
Gad-el-Mawla N; Hamza MR; Zikri ZK; Elserafi M; el-Khodari A; Khaled H; Gafaar R
Cancer Chemother Pharmacol; 1990; 26 Suppl():S85-6. PubMed ID: 2347057
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society.
Mross K; Bohn C; Edler L; Jonat W; Queisser W; Heidemann E; Goebel M; Hossfeld DK
Ann Oncol; 1993 Jan; 4(1):45-50. PubMed ID: 8435362
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide-based chemotherapy for previously treated lung cancer patients.
Chen YM; Liu JM; Wu MF; Wu HW; Lin WC; Tsai CM; Perng RP; Whang-Peng J
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):389-96. PubMed ID: 9699391
[TBL] [Abstract][Full Text] [Related]
17. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
18. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
[TBL] [Abstract][Full Text] [Related]
19. Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.
Paridaens R; Focan C; Michel J; Piccart M; Salamon E; Beauduin M; Closon MT; Tueni E; Vindevoghel A; Majois F
Cancer Chemother Pharmacol; 1990; 26 Suppl():S63-5. PubMed ID: 2112055
[TBL] [Abstract][Full Text] [Related]
20. High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.
Sanchiz F; Milla A
Cancer Chemother Pharmacol; 1990; 26 Suppl():S91-2. PubMed ID: 2112057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
